Human disease
Riley-Day syndrome
Mondo defines it as: “A congenital disorder caused by mutations in the IKBKAP gene. It is characterized by damage of the sympathetic and parasympathetic and sensory nervous system.”
2 disease groups in OMIA reach this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 312 | Dysautonomia | OMIA's OMIM numbers | 5 | Human disease |
35.0
|
| 1514 | Acral mutilation syndrome | OMIA's OMIM numbers | 1 | Human disease |
29.0
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
Open Targets links none of these groups' human genes to this disease.
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Albuterol | None of these genes | Phase 3 |
| Ipratropium | None of these genes | Phase 3 |
| Carbidopa Anhydrous | None of these genes | Phase 2 |
| Dexmedetomidine | None of these genes | Phase 2 |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.